1,125 results on '"Wimberger, Pauline"'
Search Results
202. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
203. Correction to: Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer
204. Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
205. Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients
206. Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12
207. Abstract 594: Image-based identification of single circulating tumor cells in ovarian cancer patients for genomic analysis
208. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
209. Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance
210. Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases
211. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
212. Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer: Results from retrospective part of HELP-ER study NOGGO TR2/ENGOT OV47-TR.
213. Health concerns in long-term survivors with ovarian cancer: Results of Expression VI–Carolin meets HANNA–Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey.
214. Schwangere mit präexistentem Diabetes oder Gestationsdiabetes im Kreißsaal
215. Präkonzeptionelle Beratung bei Diabetes mellitus
216. Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells : results from the randomized phase III DETECT III trial
217. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
218. Supplement for No Long-Term Effects of Antenatal Synthetic Glucocorticoid Exposure on Epigenetic Regulation of Stress-Related Genes
219. Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study
220. Morphologische und funktionelle Veränderungen des Beckenbodens durch Schwangerschaft und Geburt bei Verdacht auf fetale Makrosomie
221. Morphologische und funktionelle Veränderungen des Beckenbodens durch Schwangerschaft und Geburt bei Verdacht auf fetale Makrosomie
222. Pelvine Lymphonodektomie beim Vulvakarzinom - Wohl oder Übel?
223. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients
224. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC
225. Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease: An Exploratory Analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
226. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
227. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
228. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer
229. Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial
230. Abstract PS2-02: Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
231. Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
232. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
233. Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’ (EBioMedicine (2019) 43 (253–260), (S2352396419302142), (10.1016/j.ebiom.2019.03.069))
234. Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer:Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’ (EBioMedicine (2019) 43 (253–260), (S2352396419302142), (10.1016/j.ebiom.2019.03.069))
235. Additional file 6 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
236. Additional file 8 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
237. Additional file 2 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
238. Additional file 1 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
239. Additional file 7 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
240. Additional file 5 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
241. Additional file 3 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
242. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
243. The effect of surgical techniques on sexuality and global quality of life (Qol) in women with ovarian germ cell (OGCT) and sex cord stromal tumours (SCST) : An analysis of the AGO-CORSETT database
244. European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer
245. Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study
246. Breast cancer risk inBRCA1/2mutation carriers and noncarriers under prospective intensified surveillance
247. Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.
248. Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
249. Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study
250. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.